Trial Profile
A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M Delayed-release Capsules to Induce Remission in Patients With Active, Mild to Moderate Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Aug 2020
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Holy Stone Healthcare
- 02 Apr 2019 Status changed from recruiting to completed.
- 20 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.
- 20 Feb 2019 Planned primary completion date changed from 1 Nov 2018 to 1 Mar 2019.